254 related articles for article (PubMed ID: 21186970)
1. Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents.
Mayes TL; Bernstein IH; Haley CL; Kennard BD; Emslie GJ
J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):513-6. PubMed ID: 21186970
[TBL] [Abstract][Full Text] [Related]
2. A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children.
Jain S; Carmody TJ; Trivedi MH; Hughes C; Bernstein IH; Morris DW; Emslie GJ; Rush AJ
J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1204-1212. PubMed ID: 17712244
[TBL] [Abstract][Full Text] [Related]
3. Psychometric Properties and Factor Structures of the Korean Version of Children's Depression Rating Scale-Revised.
Kim KM; Nam S; Choi JW; Jung AH; Hong SB; Kim JW; Kim SY; Kim E; Kim JW
J Child Adolesc Psychopharmacol; 2018 May; 28(4):285-292. PubMed ID: 28771381
[TBL] [Abstract][Full Text] [Related]
4. Childhood depression subscales using repeated sessions on Children's Depression Rating Scale - revised (CDRS-R) scores.
Isa A; Bernstein I; Trivedi M; Mayes T; Kennard B; Emslie G
J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):318-24. PubMed ID: 25137188
[TBL] [Abstract][Full Text] [Related]
5. Psychometric Properties of the Patient Health Questionnaire-9 Modified for Major Depressive Disorder in Adolescents.
Nandakumar AL; Vande Voort JL; Nakonezny PA; Orth SS; Romanowicz M; Sonmez AI; Ward JA; Rackley SJ; Huxsahl JE; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):34-40. PubMed ID: 30388048
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review: The Measurement Properties of the Children's Depression Rating Scale-Revised in Adolescents With Major Depressive Disorder.
Stallwood E; Monsour A; Rodrigues C; Monga S; Terwee C; Offringa M; Butcher NJ
J Am Acad Child Adolesc Psychiatry; 2021 Jan; 60(1):119-133. PubMed ID: 33130251
[TBL] [Abstract][Full Text] [Related]
7. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
Findling RL; McCusker E; Strawn JR
J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
[No Abstract] [Full Text] [Related]
9. A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales.
Zhang CY; Voort JLV; Yuruk D; Mills JA; Emslie GJ; Kennard BD; Mayes T; Trivedi M; Bobo WV; Strawn JR; Athreya AP; Croarkin PE
J Child Adolesc Psychopharmacol; 2022 Jun; 32(5):278-287. PubMed ID: 35704877
[No Abstract] [Full Text] [Related]
10. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
[TBL] [Abstract][Full Text] [Related]
11. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
Radecki DT; Robieson WZ; Gopalkrishnan M; Greenberg E; Aziz M
J Child Adolesc Psychopharmacol; 2024 Jun; 34(5):241-250. PubMed ID: 38700708
[No Abstract] [Full Text] [Related]
13. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
Bondar J; Caye A; Chekroud AM; Kieling C
Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
[TBL] [Abstract][Full Text] [Related]
14. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
[TBL] [Abstract][Full Text] [Related]
15. [Children's Depression Rating Scale-Revised (CDRS-R): development of a German version and psychometric properties in a clinical sample].
Keller F; Grieb J; Ernst M; Spröber N; Fegert JM; Kölch M
Z Kinder Jugendpsychiatr Psychother; 2011 May; 39(3):179-85. PubMed ID: 21563109
[TBL] [Abstract][Full Text] [Related]
16. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
Kondo DG; Sung YH; Hellem TL; Fiedler KK; Shi X; Jeong EK; Renshaw PF
J Affect Disord; 2011 Dec; 135(1-3):354-61. PubMed ID: 21831448
[TBL] [Abstract][Full Text] [Related]
17. Children's Depression Inventory (CDI) and the Children's Depression Rating Scale-Revised (CDRS-R): reliability of the Hebrew version.
Zalsman G; Misgav S; Sommerfeld E; Kohn Y; Brunstein-Klomek A; Diller R; Sher L; Schwartz J; Shoval G; Ben-Dor DH; Wolovik L; Oquendo MA
Int J Adolesc Med Health; 2005; 17(3):255-7. PubMed ID: 16231477
[TBL] [Abstract][Full Text] [Related]
18. Item Response Analyses of the Children's Depression Rating Scale-Revised Using Data from Clinical Studies.
Yoshimatsu H; Imaeda T; Yoshiyama T; Higa S; Nomoto K
J Child Adolesc Psychopharmacol; 2022 May; 32(4):224-232. PubMed ID: 35544171
[No Abstract] [Full Text] [Related]
19. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
Emslie GJ; Rush AJ; Weinberg WA; Kowatch RA; Hughes CW; Carmody T; Rintelmann J
Arch Gen Psychiatry; 1997 Nov; 54(11):1031-7. PubMed ID: 9366660
[TBL] [Abstract][Full Text] [Related]
20. Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.
Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Zhu L; Tao R; Hughes C; Croarkin P
J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):21-8. PubMed ID: 22257126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
